An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1677-1683

  Aschebrook Kilfoy, Briseis ^a   Caces, Donne Bennett D ^a   Ollberding, Nicholas J ^a   Smith, Sonali M ^a   Chiu, Brian C H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Age specific temporal trends; Gender; Incidence; Mantle cell lymphoma; MCL; Racial disparities

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CAUCASIAN; ETHNICITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; SEX RATIO; TREND STUDY; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INCIDENCE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 84880252982     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.760041     Document Type: Article

References (29)

1. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unifi cation of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16: 637-640
2. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006 ; 107 : 265-276
3. Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: Non-Hodgkin slymphoma incidence by histologic subtype in the United States from 1978 through 1995. JNatl Cancer Inst 2000 ; 92 : 1240-1251
4. Li J Y, Gaillard F, Moreau A, et a l. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999 ; 154 : 1449-1452
5. Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011 ; 21 : 293-298
6. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008 ; 113 : 791-798
7. Barouk-Simonet E, Andrieux J, Copin MC, et al. TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma. Ann Genet 2002; 45: 165-168
8. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades. Hum Pathol 2002 ; 33 : 7-20
9. US National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) limited-use data set. November 2011. Available from : http://seer.cancer.gov/data/
10. Zippin C, Lum D, Hankey B F. Completeness of hospital cancer case reporting from the SEER program of the National Cancer Institute. Cancer 1995; 76 : 2343-2350
11. Surveillance Research Program. 2012 National Cancer Institute SEER . Stat software, version 7.0.6. Available from : Www.seer.cancer. gov/seerstat
12. Fay MP. Approximate confi dence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theory Methods 1999 ; 28 : 2141-2160
13. Fay MP, Tiwari RC, Feuer EJ, et al. Estimating average annual percent change for disease rates without assuming constant change. Biometrics 2006 ; 62 : 847-854
14. Clegg LX, Reichman ME, Hankey BF, et al. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: Implications for health disparity studies. Cancer Causes Control 2007 ; 18 : 177-187
15. Nambiar M, Raghavan SC. Prevalence and analysis of t(14;18) and t(11;14) chromosomal translocations in healthy Indian population. Ann Hematol 2010 ; 89 : 35-43
16. Janz S, Potter M, Rabkin CS. Lymphoma-And leukemiaassociated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer 2003 ; 36 : 211-223
17. Dö l ken G, Dö l ken L, Hirt C, et a l. Age-dependent prevalence and frequency of circulating t(14;18)-positive cells in the peripheral blood of healthy individuals. JNatl Cancer Inst Monogr 2008 ; (39) : 44-47
18. Lecluse Y, Lebailly P, Roulland S, et al. t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals. Leukemia 2009 ; 23 : 1190-1193
19. Smith MR, Joshi I, Jin F, et al. Murine model for mantle cell lymphoma. Leukemia 2006; 20: 891-893
20. Chiu BC, Dave BJ, Blair A, et al. Agricultural pesticide use and risk of t(14;18)-defi ned subtypes of non-Hodgkin lymphoma. Blood 2006 ; 108 : 1363-1369
21. Schroeder JC, Olshan AF, Baric R, et al. Agricultural risk factors for t(14;18) subtypes of non-Hodgkin slymphoma. Epidemiology 2001 ; 12 : 701-709
22. Chiu BC, Lan Q, Dave BJ, et al. The utility of t(14;18) in understanding risk factors for non-Hodgkin lymphoma. JNatl Cancer Inst Monogr 2008 ; 39 : 69-73
23. Davis DL, Rall DP. Approach to prevention. In : Rosenstock L, Cullen MR, editors. Textbook of clinical occupational and environmental medicine. Philadelphia: Saunders; 1994. pp. 615-620
24. Day NE, Charnay B. Time trends, cohort effects, and aging as infl uence on cancer incidence. In : Magnus K, editor. Trends in cancer incidence: Causes and practical implications. Washington, DC: Hemisphere; 1982. pp. 51-65
25. Beral V, Newton R. Overview of the epidemiology of immunodeficiency- Associated cancers. JNatl Cancer Inst Monogr 1998 ; 23 : 1-6
26. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009 ; 114 : 1469-1476
27. Pérez-G al á n P, Dreyling M, Wiestner A. Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011 ; 117 : 26-38
28. Martin P, Smith M, Till B. Management of mantle cell lymphoma in the elderly. Best Pract Res Clin Haematol 2012 ; 25 : 221-231
29. Overview of the SEER Program. National Cancer Institute Surveillance Epidemiology and End Results. Available from : Http:// seer.cancer.gov/about/